Opinion|Videos|March 11, 2025
Quality of Life and Patient Outcomes in mCRC Treatment
Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC?
- In your experience, how have the third-line therapy options impacted your patients’ quality of life?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps
5